Montreal, Toronto, Vancouver (July 4, 2023) – The adMare Academy invites executives working in life sciences companies across Canada to apply to be part of Cohort VI of the Executive Institute.
Read More
Ottawa, May 31, 2023 – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that nominations are now open for the 2023 Diversity and Equity in Research Award. This new award recognizes a remarkable individual whose research demonstrates the highest quality of excellence and advances equitable participation in health research and access to health care in Canada, improving the well-being of all Canadians, particularly those facing inequities.
Read More
GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the “Arrangement”). The Arrangement was approved by BELLUS’ shareholders on 16 June 2023.
Read More
OTTAWA, ON, June 20, 2023 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) launched a new 60-day Notice and Comment period today, encouraging stakeholders and interested members of the public to provide their input on new proposed Interim Guidance.
Read More
QUÉBEC CITY, June 13, 2023 /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.
Read More
One of Aplantex’ technical partners, the Centre d’études des procédés chimiques du Québec (CEPROCQ) represented by Yacine Boumghar, Ph.D, has received a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support the continued development of Aplantex’ innovative process to produce valuable molecules commonly used by the pharmaceutical, cosmetics, and agrifood industries.
Read More
BOSTON — The Manitoba government’s visionary new Life Sciences Strategy will power innovation and boost the province’s reputation as an internationally renowned hub for biosciences, Economic Development, Investment and Trade Minister Jeff Wharton announced today at the BIO International Convention in Boston.
Read More
MONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of Neomabs Biotechnologies, a new Montreal-based biotechnology company specializing in the discovery and development of innovative oncology therapies.
Read More
BOSTON, June 6, 2023 /PRNewswire/ - Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform technology to engineer and develop novel protein subunit vaccines, today announced a clinical supply agreement with Biodextris Inc.
Read More
Boston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research.
Read More
MONTREAL and BOSTON, June 5, 2023 /CNW/ - Oncopole, Fonds de recherche du Québec - Santé (FRQS) cancer division, is proud to announce major investments that bolster its unique public-private partnership model dedicated to the fight against cancer. Building on its dynamism and ability to mobilize stakeholders in the life sciences community, Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada.
Read More
Montreal, Toronto, Vancouver (June 6, 2023) – adMare BioInnovations, a leader in the Canadian life sciences sector, is pleased to announce the launch of the adMare Institute, a new voice aimed at advancing the life sciences and related public policy in Canada. The announcement was made today at the prestigious BIO International Conference in Boston.
Read More
MONTREAL, June 5, 2023 /PRNewswire/ - Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.
Read More
Grant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.
MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.
Read More
Boston (Massachussetts), June 5, 2023 – At the 2023 BIO International Convention BIOQuébec and MassBio agreed to extend their existing memorandum of cooperation and collaboration for a 3-year period. This agreement, originally initiated in 2017 and renewed in 2019 at the same conference aims to facilitate business ties between their respective members and support the market development initiatives of both Québec and Massachusetts-based biotechnology sector companies.
Read More
creation and exchange of innovative ideas.
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal. Located in the iconic Place Gare Viger, the office has been designed to provide a modern workplace that meets the needs of Novartis' associates and facilitates closer collaboration with key stakeholders.
Read More
Pfizer Canada ULC announces the launch of its Healthcare Hub, an initiative with Canadian tech and innovation startups to scale up health solutions, with the goal of enhancing outcomes and the patient experience in important areas of need in Canadian healthcare.
Read More
enGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.
Read More
The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph through a partnership with OmniaBio Inc., CCRM and the university. The training program, to begin in summer 2023, will cater to recent post-secondary graduates, industry professionals and companies growing their roster of clean room manufacturing staff. The fast growth of cell and gene therapies (CGTs) has made it a challenge for the global industry to keep up with talent requirements. This new CGT technical training site will begin to address the industry's critical training needs and represents the first stage of a larger, multi-site training strategy for CATTI.
Read More
BIOQuébec: a powerful facilitator for your organization
When Anie Perrault, then executive director, met Frédéric Leduc for the first time in 2014, she convinced him to become a member by highlighting the benefits of a strong, extensive network and the possibility of makinghis voice heard via BIOQuébec. Frédéric immediately seized this unique opportunity to meet potential clients and collaborators for the young biotech he had co-founded.
Read More